Introductory Study Of The Once-a-month, Injectable Contraceptive Cyclofem® In Brazil, Chile, Colombia, And Peru

An introductory trial with the injectable contraceptive Cyclofem® was carried out in Brazil, Chile, Colombia, and Peru, with participation by 3,183 women. Women were followed-up for up to 2 years of use and the data were evaluated by life table analysis. A total of 29,676 women-months were accumulated for up to 2 years. No pregnancies were observed in the 2 years. The discontinuation rates for amenorrhea in the first year ranged from 3.4 in Brazil to 8.1 in Colombia, and for menstrual disturbances from 5.1 in Chile to 9.2 in Brazil. The discontinuation rates for other medical reasons ranged from 7.8 in Brazil to 26.3 in Colombia, and for personal reasons from 17.2 in Chile to 23.5 in Brazil. Continuation rates ranged from 42.3 in Colombia to 52 in Chile. In the second year of observation the rates of discontinuation were lower than those observed in the first year, with the exception of personal reasons in Brazil, which were the same as those observed in the first year. Continuation rates ranged from 19.4 in Brazil to 36.8 in Chile. The comparison of reasons for discontinuation in selected clinics showed that the rate for amenorrhea in one clinic in Chile was more than three times that in others and in Peru was seven times more in one clinic than in another. Regarding menstrual disturbances, in Peru one clinic presented a rate three times higher than the others. The main reasons for discontinuation due to other medical reasons were headache and weight gain. In conclusion, Cyclofem presented a high contraceptive efficacy and an acceptable rate of continuation and discontinuation for up to 2 years in the four countries.The performance of the monthly injectable contraceptive, Cyclofem, was evaluated in an introductory trial involving 3183 women recruited from family planning centers in Brazil, Chile, Colombia, and Peru. A total of 29,676 women-months of use were accumulated during up to 2 years of follow-up. No pregnancies occurred during the study period. Discontinuation rates per 100 women in the first year ranged from 3.4 in Brazil to 8.1 in Colombia for amenorrhea and from 5.1 in Chile to 9.2 in Brazil for menstrual disturbances. The discontinuation rate for other medical reasons (primarily headache, weight gain, and acne) ranged from 7.8 in Brazil to 26.3 in Colombia and for personal reasons from 17.2 in Chile to 23.5 in Brazil. First-year continuation rates ranged from 42.3 in Colombia to 52.0 in Chile. In the second year of use, continuation rates ranged from 19.4 in Brazil to 36.8 in Chile. Upon receiving these results, national regulatory authorities in the 4 participating countries approved Cyclofem registration. Acceptance of injectable contraception, which currently entails administration of the method by a service provider and travel to a clinic, could be improved in developing countries by training in self-administration.566353359(1991) Contraceptive Requirements and Demand for Contraceptive Commodities in Developing Countries in the 1990s, , New York: United Nations Population Fund (UNFPA)Hall, P., The introduction of Cyclofem into national family planning programmes: Experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia (1994) Contraception, 49, pp. 489-507Facts about once-a-month injectable contraceptives: Memorandum from a WHO meeting (1993) Bull WHO, 71, pp. 677-689Newton, J.R., D'Arcangues, C., Hall, P.E., A review of "once-a-month" combined injectable contraceptives (1994) J Obstet Gynaecol, 14 (SUPPL. 1), pp. S1-S34Improving access to quality care in family planning (1996) Medical Eligibility Criteria for Contraceptive Use, , Geneva: World Health OrganizationArmitage, P., Berry, G., (1985) Statistical Methods in Medical Research, 2nd Ed., , Oxford: Blackwell Scientific PublicationsSpicehandler, J., Simmonns, R., Contraceptive introduction reconsidered: A review and conceptual framework (1994) UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, , WHO/HRP/ITT/94.1, Geneva(1991) Colombia. Demographic and Health Survey, 1990, , PROFAMILIA and Macro International Inc(1992) Peru. Demographic and Health Survey, 1991/1992, , Instituto Nacional de Estadística e Informática, PRISMA and Macro International Inc(1997) Brazil. Demographic and Health Survey, 1996, , BENFAM and Macro International IncBruce, J., Fundamental elements of the quality of care: A simple framework (1989) The Population Council, Working Papers, , New York, MayHassan, E., El-Nahal, N., El-Hussein, M., Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt (1994) Contraception, 49, pp. 469-488A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular in-jection. II. The comparison of bleeding patterns (1989) Contraception, 40, pp. 531-551Bahamondes, L., Lavin, P., Ojeda, G., Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem (1997) Contraception, 57, pp. 307-310Bahamondes, L., Marchi, N., Cristofoletti, M.L., Uniject as a delivery system for the once-a-month injectable contraceptive Cyclofem in Brazil (1996) Contraception, 53, pp. 115-119Bahamondes, L., Marchi, N.M., Nakagava, H.M., Self-administration with uniject of the once-a-month injectable contraceptive Cyclofem (1997) Contraception, 56, pp. 301-30